Pipeline Prowess: Can GSK's Acceleration Be Enough? GSK plc's latest financial results and strategic plans have sent shockwaves through the pharmaceutical industry.
On the surface, the company's strong core operational performance and commercial momentum are undeniable – £8. 4 billion in turnover, up 5% year over year at constant exchange rates, is a notable achievement.
However, beneath this façade lies a more nuanced story of growth, risk, and opportunity. While the Specialty Medicines segment boasts a 14% increase in sales, total operating profit takes a significant hit due to a £1.